JP2025508380A5 - - Google Patents

Info

Publication number
JP2025508380A5
JP2025508380A5 JP2024547662A JP2024547662A JP2025508380A5 JP 2025508380 A5 JP2025508380 A5 JP 2025508380A5 JP 2024547662 A JP2024547662 A JP 2024547662A JP 2024547662 A JP2024547662 A JP 2024547662A JP 2025508380 A5 JP2025508380 A5 JP 2025508380A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
cancer
acid sequences
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508380A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/053720 external-priority patent/WO2023156434A1/en
Publication of JP2025508380A publication Critical patent/JP2025508380A/ja
Publication of JP2025508380A5 publication Critical patent/JP2025508380A5/ja
Pending legal-status Critical Current

Links

JP2024547662A 2022-02-16 2023-02-15 B7-h4抗体薬物複合体を含む、癌の処置のための組み合わせ療法 Pending JP2025508380A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263310967P 2022-02-16 2022-02-16
US63/310,967 2022-02-16
US202263378295P 2022-10-04 2022-10-04
US63/378,295 2022-10-04
PCT/EP2023/053720 WO2023156434A1 (en) 2022-02-16 2023-02-15 Combination therapies for treatment of cancer comprising b7-h4 antibody drug conjugate

Publications (2)

Publication Number Publication Date
JP2025508380A JP2025508380A (ja) 2025-03-26
JP2025508380A5 true JP2025508380A5 (https=) 2026-02-24

Family

ID=85283493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547662A Pending JP2025508380A (ja) 2022-02-16 2023-02-15 B7-h4抗体薬物複合体を含む、癌の処置のための組み合わせ療法

Country Status (13)

Country Link
US (1) US20230310636A1 (https=)
EP (1) EP4479428A1 (https=)
JP (1) JP2025508380A (https=)
KR (1) KR20240150781A (https=)
AU (1) AU2023221516A1 (https=)
CA (1) CA3250868A1 (https=)
CL (1) CL2024002434A1 (https=)
CO (1) CO2024012148A2 (https=)
CR (1) CR20240385A (https=)
IL (1) IL314797A (https=)
MX (1) MX2024009972A (https=)
TW (1) TW202348252A (https=)
WO (1) WO2023156434A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025103407A1 (zh) * 2023-11-16 2025-05-22 江苏豪森药业集团有限公司 抗体药物偶联物和多腺苷二磷酸核糖聚合酶抑制剂的联合应用
TW202539742A (zh) * 2024-02-08 2025-10-16 大陸商上海翰森生物醫藥科技有限公司 抗體藥物偶聯物和抗vegf抗體的聯合應用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE229046T1 (de) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001002588A2 (en) 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
ZA200503075B (en) 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
WO2015155345A1 (en) 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
WO2016040724A1 (en) * 2014-09-12 2016-03-17 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor
EP3612567B1 (en) * 2017-04-19 2024-09-11 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
MX2021011812A (es) 2019-03-29 2021-10-22 Medimmune Ltd Compuestos y conjugados de estos.
SI3999506T1 (sl) 2019-07-19 2025-06-30 Astrazeneca Ab Zaviralci PARP1
BR112023004415A2 (pt) 2020-09-11 2023-05-09 Medimmune Ltd Moléculas terapêuticas de ligação a b7-h4

Similar Documents

Publication Publication Date Title
JP7850455B2 (ja) 抗cubドメイン含有タンパク質1(cdcp1)抗体、抗体薬物コンジュゲート、およびその使用方法
US20230073692A1 (en) Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof
US8309094B2 (en) Antibody-drug conjugates
JP2010535713A5 (https=)
TW202019487A (zh) 抗體-藥物結合物及微管蛋白抑制劑之組合
JP2026049000A (ja) 抗sez6l2抗体および抗体薬物コンジュゲート
CN113784987B (zh) 靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
JP2017500028A5 (https=)
EP3082873A1 (en) Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses
JP2025508380A5 (https=)
JP2025507817A5 (https=)
JP2023500385A5 (https=)
WO2025131054A1 (en) Antibody drug conjugates targeting to b7-h3 and egfr and the use thereof
HK40114669A (zh) 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
WO2023025303A1 (zh) 抗cldn-18.2抗体药物偶联物及其用途
WO2026021442A1 (zh) 抗体药物偶联物在制备治疗肺癌的药物中的用途
HK40113035A (zh) 抗sez6l2抗体和抗体药物缀合物
HK40089485A (zh) 抗cldn-18.2抗体药物偶联物及其用途
HK40089485B (zh) 抗cldn-18.2抗体药物偶联物及其用途
RU2025134256A (ru) Конъюгат антитела к pdl1 и лекарственного средства и применение
HK40014209B (zh) 抗-含cub结构域蛋白1 (cdcp1)抗体、抗体药物缀合物及其使用方法
NZ615308B2 (en) Antibody-drug conjugates